TESARO Inc (TSRO) was Initiated by FBR Capital to “Outperform” and the brokerage firm has set the Price Target at $65. FBR Capital advised their investors in a research report released on Apr 13, 2016.
Many Wall Street Analysts have commented on TESARO Inc. Sun Trust Rbsn Humphrey Initiated TESARO Inc on Mar 2, 2016 to “Buy”, Price Target of the shares are set at $60.Lake Street Initiated TESARO Inc on Feb 5, 2016 to “Buy”, Price Target of the shares are set at $61.Wedbush Initiated TESARO Inc on Jan 21, 2016 to “Outperform”, Price Target of the shares are set at $72.
On the company’s financial health, TESARO Inc reported $-1.89 EPS for the quarter, missing the analyst consensus estimate by $ -0.16 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $-1.73. The company had revenue of $.23 million for the quarter, compared to analysts expectations of $2.85 million. During the same quarter in the previous year, the company posted $-1.33 EPS.
TESARO Inc closed down -0.64 points or -1.42% at $44.56 with 5,71,341 shares getting traded on Monday. Post opening the session at $45.47, the shares hit an intraday low of $43.58 and an intraday high of $46.285 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price. According to the SEC, on Mar 18, 2016, Arnold L Oronsky (director) purchased 142,085 shares at $35.19 per share price. On Mar 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $43.54 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.